The Wegovy Tablet is oral semaglutide — the same active medicine as the Wegovy injection, redesigned as a once-daily tablet. On 11 June 2026 the Medicines and Healthcare products Regulatory Agency (MHRA) approved it for weight management, making it the first GLP-1 weight-loss medicine you can take by mouth in the UK. If you have been putting off treatment because you dislike needles, this is a genuine alternative, and it works through the same appetite-regulating mechanism as the injection.
It is not, however, a shortcut or an over-the-counter option. Like every GLP-1 medicine, the Wegovy Tablet is prescription-only. It is supplied only after an online consultation and a clinical assessment by a prescriber, who checks that it is appropriate and safe for you. This guide explains what oral semaglutide actually is, how it differs from the injection, where it sits in UK law and licensing, how it is dosed, what side effects to expect, and who it tends to suit.
What is oral semaglutide?
Semaglutide is a GLP-1 receptor agonist. It imitates a natural gut hormone called glucagon-like peptide-1, which your body releases after you eat. That signal does three useful things: it dampens appetite so you feel hungry less often, it slows how quickly your stomach empties so you feel full for longer, and it improves the way your body handles blood sugar after meals. The net effect for most people is that they eat less without the constant white-knuckle effort that usually defines dieting.
The Wegovy Tablet delivers that same molecule, but as a tablet you swallow rather than a medicine you inject. That sounds simple, but it is a real feat of pharmaceutical engineering. Semaglutide is a peptide — essentially a small protein — and the gut is built to break proteins down before they can reach the bloodstream. To get around that, the tablet is co-formulated with an absorption enhancer called SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate). SNAC creates a small, temporary local environment in the stomach that protects the semaglutide and helps a useful amount of it cross into the blood.
That chemistry is also why the tablet has to be taken in a specific way, which we cover below. Take it wrong and much of the dose simply does not get absorbed.
How is the Wegovy Tablet different from the injection?
The most important thing to understand is that the tablet and the injection are the same drug, not two different medicines. Both are semaglutide, and both act on the GLP-1 receptor in the same way. The differences are about format, dose, and how the medicine gets into your system — not about what it is.
Here is a side-by-side comparison.
| Feature | Wegovy Tablet (oral semaglutide) | Wegovy injection |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| How you take it | One tablet, once daily | One injection, once weekly |
| How it's taken | Empty stomach, plain water, wait 30 minutes | Under the skin (stomach, thigh or upper arm), any time of day |
| Needles | None | Yes (very fine, pre-filled pen) |
| Maintenance dose | 25 mg once daily | 2.4 mg once weekly |
| Trial evidence | OASIS-4 (oral 25 mg) | STEP-1 (injection 2.4 mg) |
| Best suited to | People who prefer a tablet and can keep to the empty-stomach routine | People who prefer a weekly routine and don't mind injecting |
Two points are worth drawing out. First, the doses look wildly different — 25 mg versus 2.4 mg — but that is expected. Far less of an oral peptide survives digestion, so a much larger dose is needed to achieve a similar amount of medicine in the blood. The numbers are not comparable across formats, and a bigger figure does not mean a stronger effect.
Second, the daily-versus-weekly trade-off cuts both ways. A weekly injection is easy to forget in a good way — you do it once and you are done. A daily tablet asks for a small piece of discipline every single morning, but it removes needles entirely. Neither is objectively better; it depends on which routine you will actually stick to. If you want to weigh the injectable options too, our Wegovy injection page and the Mounjaro page set them out in the same detail, and you can compare all treatments here.
Is the Wegovy Tablet available in the UK — and is it the same as Rybelsus?
This is where a lot of online information is out of date or simply wrong, so it is worth being precise.
The Wegovy Tablet is oral semaglutide at 25 mg once daily, licensed by the MHRA for weight management in adults with obesity, or overweight with a related health condition. That approval came on 11 June 2026, and it is the first tablet form of a GLP-1 medicine to be licensed for weight loss in the UK.
Rybelsus is different. Rybelsus is also oral semaglutide, but at lower doses (typically up to 14 mg daily) and it is licensed only for type 2 diabetes, not for weight loss. You may see articles online suggesting you can "buy Rybelsus for weight loss" — prescribing it purely for weight management would be off-licence, and it is not the same product as the higher-dose Wegovy Tablet. When people search for the "Wegovy Tablet UK," the medicine they usually mean is the 25 mg weight-management tablet, not Rybelsus.
So: yes, the Wegovy Tablet is available in the UK, and yes, it is genuinely licensed for weight loss — but only as a prescription-only medicine, supplied after a proper clinical assessment. You can read the full product detail, dosing and current availability on our dedicated Wegovy Tablet page.
How well does oral semaglutide work?
Efficacy claims for weight-loss medicines should always be tied to a named clinical trial, so here is the evidence rather than a marketing number.
The higher-dose oral semaglutide used in the Wegovy Tablet was studied in the OASIS phase-3 programme. One important thing to understand before reading any weight-loss trial is that results are usually reported under two different statistical "estimands," and they answer slightly different questions. The treatment-policy estimand counts everyone as they were randomised — including people who stopped the medicine or started other treatments — so it reflects the real-world average across a whole group. The efficacy (adherent) estimand describes what happened in people who actually kept taking the medicine as intended. Both are valid; they simply are not the same number, and it is misleading to mix figures from the two.
In OASIS-4, adults with overweight or obesity taking oral semaglutide 25 mg once daily lost, on the treatment-policy estimand, an average of around 13.6% of their body weight over roughly 64 weeks, compared with about 2.2% in the placebo group (Garvey et al., New England Journal of Medicine, 2025). On the efficacy (full-adherence) estimand — that is, among people who stayed on treatment — mean weight loss was higher, at around 16.6%. It is from that same efficacy analysis that roughly one third of participants lost 20% or more of their body weight, versus about 3% on placebo. These responder figures belong to the adherent analysis, not to the 13.6% treatment-policy average, so they should not be read as one combined result.
Whichever figure you look at, the same caveat applies: results vary, and not everyone reaches these numbers. Every one of these outcomes was achieved alongside a reduced-calorie diet and increased physical activity, and the medicine supports those changes rather than replacing them. Trial averages describe a group, not an individual — some people lose considerably more, some lose less, and how much you tolerate and how consistently you take the medicine both matter.
For context, the Wegovy injection was studied in the STEP-1 trial, where semaglutide 2.4 mg weekly produced a mean weight loss of about 14.9% over 68 weeks, versus about 2.4% on placebo (Wilding et al., New England Journal of Medicine, 2021) — again alongside a reduced-calorie diet and increased activity, and again with the same "results vary" caveat. These figures come from separate trials with different designs, durations and estimands, so they are not a head-to-head comparison — you cannot conclude that one format is stronger than the other from these numbers alone.
Who might the Wegovy Tablet suit?
In UK private practice, GLP-1 weight-loss medicines are prescribed within the medicine's MHRA marketing authorisation. The Weight Clinic is a private prescriber operating under that licence, and the licensed weight-management thresholds are generally:
- a BMI of 30 or above (obesity); or
- a BMI of 27 or above with a weight-related health condition — for example type 2 diabetes, high blood pressure, high cholesterol or obstructive sleep apnoea.
A slightly lower threshold may apply for people from some ethnic backgrounds — including South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds — because health risks from excess weight can appear at a lower BMI.
It is worth being clear that this MHRA-licensed private threshold is not the same as the NHS-funding bar, which is stricter. NICE, which decides what the NHS will fund, recommends semaglutide (technology appraisal TA875) only for adults with a weight-related comorbidity who also have a BMI of 35 or above, or a BMI of 30–34.9 who meet the criteria for a specialist weight-management service — and then only within such a service, for a maximum of two years. So a person can be eligible for treatment privately, under the MHRA licence, without meeting the tighter threshold the NHS uses to decide funding.
Beyond the numbers, the tablet tends to suit people who:
- would genuinely prefer a tablet to an injection;
- can reliably keep to the empty-stomach dosing routine every morning; and
- are ready to support the medicine with a reduced-calorie diet and increased activity.
The tablet is generally not suitable if you are pregnant, planning pregnancy or breastfeeding; have type 1 diabetes; have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2); have had pancreatitis; have severe gastrointestinal disease such as gastroparesis; have an active eating disorder; or are allergic to semaglutide. These lists are not exhaustive, which is exactly why a prescriber reviews your full history before anything is prescribed.
How to take the Wegovy Tablet correctly
Because of the SNAC absorption chemistry, the dosing routine is not optional — get it wrong and the medicine barely works. The instructions are:
- Take one tablet first thing in the morning, on an empty stomach, before anything else.
- Swallow it with a small sip of plain water only — no more than about 120 ml (roughly half a glass).
- Then wait at least 30 minutes before eating, drinking anything else, or taking other medicines or supplements.
Taken with food, or with too much water, or too close to other tablets, the tablet is significantly less effective. Treatment also starts low and increases gradually — this titration (a low starter dose stepped up over weeks) gives your body time to adjust and keeps side effects more manageable. You do not begin on the full 25 mg dose.
How it works at The Weight Clinic
The Weight Clinic is a GPhC-registered UK online pharmacy and a private prescriber. Every treatment we supply is prescription-only and is only ever dispensed after a clinician has reviewed you.
The process is straightforward. You start with a free online eligibility check — a short medical questionnaire, with no card details needed to begin. One of our prescribers reviews your answers and history, and if a GLP-1 medicine is clinically appropriate, they recommend the option that fits you best. If it is not right for you, they will tell you, and explain why. Your medicine is then dispensed from our own in-house pharmacy, with our clinical team available for questions throughout. There is no subscription and no lock-in.
On pricing, we keep it simple: the Wegovy Tablet starts from £80 for your first month (£115 standard, with £35 off your first order using code NEWME), and the injectable Wegovy and Mounjaro options are priced transparently on their own pages. You only pay for the medicine, and you can get a full refund any time before dispatch.
If you are wondering whether oral semaglutide is right for you, the honest answer is that it depends on your health, and that is a question for a clinician rather than a web page.
Check your eligibility — it is free, takes a few minutes, and a UK-registered prescriber reviews every answer.
Side effects and safety: an honest summary
No effective medicine is free of side effects, and the Wegovy Tablet shares the well-documented profile of the GLP-1 class. Most reactions are gastrointestinal, are most common when you start or increase the dose, and usually ease over a few weeks as your body adjusts.
Common effects (may affect more than 1 in 10 people): nausea, diarrhoea, constipation, vomiting, reduced appetite and tiredness. Starting on a low dose and increasing slowly is designed specifically to keep these manageable.
Less common effects: dizziness, abdominal pain, burping or bloating, hair thinning, gallstones, and low blood sugar (mainly relevant if you also take medicines for type 2 diabetes).
Serious but rare effects — seek medical help promptly: the most important of these is acute pancreatitis (inflammation of the pancreas). The MHRA describes pancreatitis as a known but infrequent side effect of GLP-1 medicines, with rare severe or necrotising cases reported. The red-flag warning sign is severe, persistent abdominal pain that may radiate through to your back, sometimes with vomiting — if that happens, stop taking the medicine and seek urgent medical care. Gallbladder problems and gallstones can also occur, as can a serious allergic reaction, severe low blood sugar, and — in people with type 2 diabetes — possible worsening of diabetic eye disease. These are uncommon, but you should know the warning signs.
Two safety points apply to everyone. First, if you experience any side effect — expected or not — tell your clinician, and you can report it directly through the MHRA Yellow Card scheme, which helps the regulator monitor the safety of all UK medicines. Second, always read the patient information leaflet that comes with your medicine; it is the definitive, product-specific source, and this article does not replace it or the advice of your own prescriber.
Frequently asked questions
Is the Wegovy Tablet the same as the Wegovy injection? It is the same active medicine — semaglutide — in a different form. It is taken as a tablet once a day; the injection is given under the skin once a week. Both act on the GLP-1 receptor to reduce appetite. The doses differ (25 mg daily for the tablet versus 2.4 mg weekly for the injection) because far less of an oral peptide is absorbed, so the figures are not directly comparable.
Can I buy the Wegovy Tablet in the UK without a prescription? No. Oral semaglutide is a prescription-only medicine. It can only be supplied after an online consultation and a clinical assessment by a prescriber, who checks that it is appropriate and safe for you. Anywhere offering it "without a prescription" is not operating legally or safely.
Is the Wegovy Tablet the same as Rybelsus? No. Both are oral semaglutide, but Rybelsus is a lower dose licensed only for type 2 diabetes, not weight loss. The Wegovy Tablet is higher-dose oral semaglutide (25 mg) licensed by the MHRA specifically for weight management.
How much weight could I lose on oral semaglutide? In the OASIS-4 trial, people taking oral semaglutide 25 mg lost on average about 13.6% of their body weight over roughly 64 weeks on the treatment-policy estimand (versus about 2.2% on placebo); among people who kept taking it (the efficacy estimand) the average was around 16.6%, and roughly one third lost 20% or more (Garvey et al., NEJM, 2025). These are group figures achieved alongside a reduced-calorie diet and increased activity — results vary, and not everyone reaches them. Your outcome depends on the dose you tolerate, how consistently you take it, and the changes you make.
Why does the tablet have to be taken on an empty stomach? Semaglutide is a peptide that the gut would normally break down, so the tablet uses an absorption enhancer (SNAC) to help it into the bloodstream. Food, too much water, or other medicines interfere with that absorption. Taking it first thing with a small sip of plain water and waiting 30 minutes lets the medicine work as intended.
How much does the Wegovy Tablet cost at The Weight Clinic? It starts from £80 for your first month (£115 standard, with £35 off your first order using code NEWME). Higher maintenance doses are priced transparently on the product page. There is no subscription, and you can get a full refund any time before your medicine is dispatched.
This article is for general information and does not replace advice from your own prescriber. Whether any weight-loss medicine is right for you depends on your individual health and must be assessed by a clinician.
Frequently asked questions
Is the Wegovy Tablet the same as the Wegovy injection?
It is the same active medicine — semaglutide — in a different form. It is taken as a tablet once a day; the injection is given under the skin once a week. Both act on the GLP-1 receptor to reduce appetite. The doses differ (25 mg daily for the tablet versus 2.4 mg weekly for the injection) because far less of an oral peptide is absorbed, so the figures are not directly comparable.
Can I buy the Wegovy Tablet in the UK without a prescription?
No. Oral semaglutide is a prescription-only medicine. It can only be supplied after an online consultation and a clinical assessment by a prescriber, who checks that it is appropriate and safe for you. Anywhere offering it without a prescription is not operating legally or safely.
Is the Wegovy Tablet the same as Rybelsus?
No. Both are oral semaglutide, but Rybelsus is a lower dose licensed only for type 2 diabetes, not weight loss. The Wegovy Tablet is higher-dose oral semaglutide (25 mg) licensed by the MHRA specifically for weight management.
How much weight could I lose on oral semaglutide?
In the OASIS-4 trial, people taking oral semaglutide 25 mg lost on average about 13.6% of their body weight over roughly 64 weeks on the treatment-policy estimand (versus about 2.2% on placebo); among people who kept taking it (the efficacy estimand) the average was around 16.6%, and roughly one third lost 20% or more. These are group figures achieved alongside a reduced-calorie diet and increased activity — results vary, and not everyone reaches them (Garvey et al., NEJM, 2025). Your outcome depends on the dose you tolerate, how consistently you take it, and the changes you make.
Why does the tablet have to be taken on an empty stomach?
Semaglutide is a peptide that the gut would normally break down, so the tablet uses an absorption enhancer (SNAC) to help it into the bloodstream. Food, too much water, or other medicines interfere with that absorption. Taking it first thing with a small sip of plain water and waiting 30 minutes lets the medicine work as intended.
How much does the Wegovy Tablet cost at The Weight Clinic?
It starts from £80 for your first month (£115 standard, with £35 off your first order using code NEWME). Higher maintenance doses are priced transparently on the product page. There is no subscription, and you can get a full refund any time before your medicine is dispatched.
